Injective (INJ) is currently trading at $2.91, reflecting a 3.04% decrease over the past 24 hours. The price has fluctuated between a daily high of $3.01 and a low of $2.87, indicating a relatively tight daily range of 0.14%.

Trading volume stands at approximately 27.05 million, which corresponds to a volume-to-market cap ratio of 9.29%. This suggests moderate trading activity relative to market capitalization, with interest potentially waning given the recent price decline.

Analyzing the moving averages reveals mixed signals; the 8-period SMA shows a slight increase of 0.40%, while the 13-period and 21-period SMAs indicate minimal declines. The longer-term 144-period SMA is showing a positive trend, rising by 1.75%, suggesting potential support at around $2.86.

The 1-hour Relative Strength Index (RSI) is at 34, indicating that INJ may be oversold in the short term. Conversely, the 7-day RSI sits at 53, reflecting a more neutral stance, while the 14-day and 30-day price changes are negative, suggesting downward pressure over longer periods.

Despite the recent price drop, INJ has shown a price increase of 4.55% over the past week, demonstrating some short-term resilience. However, with a significant gap from its all-time high of $52.62, the current price trajectory indicates substantial selling pressure.

Given the current technical indicators, including the bearish short-term momentum and the mixed moving average signals, the outlook for INJ appears cautious. Therefore, I recommend a Hold rating, as investors may want to wait for clearer bullish signals or a confirmed reversal before making any new positions.